Rainer Boxhammer
Planegg, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.
Journal: Nature medicine
Published: August 09, 2024
Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.
Journal: Kidney international reports
Published: June 03, 2024
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection.
Journal: The New England journal of medicine
Published: May 28, 2024
Preclinical study of CD19 detection methods post tafasitamab treatment.
Journal: Frontiers in immunology
Published: August 08, 2023
Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti-CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study.
Journal: Kidney international reports
Published: April 13, 2022
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
Journal: Trials
Published: September 25, 2021
Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy.
Journal: Cancer immunology, immunotherapy : CII
Published: June 30, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026